Acta de reunión clínica

← vista completa

Publicado el 1 de abril de 2009 | http://doi.org/10.5867/medwave.2009.04.3857

Efectos nutricionales de los anticonvulsivantes

Nutritional effects of anticonvulsants

Mario Vildoso Fernández

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Mario Vildoso Fernández

Hospital Padre Hurtado, Santiago, Chile

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Vildoso Fernández M. Nutritional effects of anticonvulsants. Medwave 2009;9(04):e3857 doi: 10.5867/medwave.2009.04.3857

Envío 01/01/1970

Aceptación 01/01/1970

Publicación 01/04/2009

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Referencias

  1. Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005 Jan;115(1):177-86. | PubMed
  2. Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol. 2002 May;59(5):781-6. | CrossRef | PubMed
  3. Burt R, Freston JW, Tolman KG. The influence of phenobarbital on biotransformation of 25-hydroxycholecalciferol. J Clin Pharmacol. 1976 Aug-Sep;16(8-9):393-8. | PubMed
  4. O'Hare JA, Duggan B, O'Driscoll D, Callaghan N. Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand. 1980 Nov;62(5):282-6. | CrossRef | PubMed
  5. Karaaslan Y, Haznedaroðlu S, Oztürk M. Osteomalacia associated with carbamazepine/valproate. Ann Pharmacother. 2000 Feb;34(2):264-5. | CrossRef | PubMed
  6. Ranganathan LN, Ramaratnam S. Rapid versus slow withdrawal of antiepileptic drugs. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005003. | PubMed
  7. Christiansen C, Rodbro P, Lund M. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. Br Med J. 1973 Dec 22;4(5894):695-701. | CrossRef | PubMed
  8. Christiansen C, Rodbro P, Nielsen CT. Iatrogenic osteomalacia in epileptic children. A controlled therapeutic trial. Acta Paediatr Scand. 1975 Mar;64(2):219-24. | PubMed
  9. Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? Crit Care. 2005 Oct 5;9(5):431-40. Epub 2005 Jun 10. | CrossRef | PubMed
  10. Greco R, Latini G, Chiarelli F, Iannetti P, Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology. 2005 Dec 13;65(11):1808-9. | CrossRef | PubMed
  11. Nabe K, Fujimoto S, Shimodahira M, Kominato R, Nishi Y, Funakoshi S, et al. Diphenylhydantoin suppresses glucose-induced insulin release by decreasing cytoplasmic H+ concentration in pancreatic islets. Endocrinology. 2006 Jun;147(6):2717-27. Epub 2006 Mar 9. | CrossRef | PubMed
  12. Wilkes JJ, Nelson E, Osborne M, Demarest KT, Olefsky JM. Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab. 2005 Mar;288(3):E617-24. Epub 2004 Nov 9. | CrossRef | PubMed